TL;DR
In a randomized trial of 584 adults with septic shock undergoing surgery in China, adding intraoperative dobutamine to norepinephrine was associated with a lower rate of new or worsening acute kidney injury within seven days. The open-label study found more tachycardia with the combination, while serious cardiac events and several other outcomes did not differ significantly. The authors describe the findings as hypothesis-generating.
A randomized trial in 584 adults with septic shock found that adding dobutamine to norepinephrine during surgery was associated with a lower incidence of new or worsening acute kidney injury (AKI) within seven days than norepinephrine alone. The findings, published in JAMA and presented at a critical care congress, offer evidence about an intraoperative treatment for patients undergoing surgery to control the source of infection.
AKI within seven days after surgery occurred in 22.8% of patients assigned to dobutamine plus norepinephrine and 34.7% assigned to norepinephrine alone. The adjusted risk ratio was 0.64, with a 95% confidence interval of 0.49 to 0.83. The trial was open-label and conducted at 39 tertiary hospitals in China; the median age of participants was 67.5, and about one-third were women.
Patients receiving the combination were given a continuous dobutamine infusion starting at 5 micrograms per kilogram per minute during surgery. In both groups, norepinephrine was adjusted to target a mean arterial pressure of 65 mm Hg. Gastrointestinal perforation was the most common reason for surgery, followed by gastrointestinal obstruction. The study tested dobutamine only during the operation, not as a continuing postoperative treatment.
On the first postoperative day, the combination group had a lower median SOFA score, a measure of organ dysfunction, than the norepinephrine-only group: 5 compared with 6. Urine output one hour after treatment began was also higher, with medians of 2.4 versus 1.9 milliliters per kilogram per hour. In exploratory analyses, stage 2 and stage 3 AKI were less frequent in the combination group; stage 1 rates were similar. These analyses were post hoc and should be interpreted cautiously.
Kidney Outcomes After Septic Shock Surgery
AKI is a serious complication for patients already facing septic shock and the stress of emergency surgery. The difference in the trial’s primary outcome suggests that supporting circulation with dobutamine alongside norepinephrine during source control may help reduce kidney injury in this setting. This matters because surgery to control an infection’s source is needed for a portion of people with septic shock, while inadequate tissue perfusion can contribute to organ damage.
The result does not establish that the combination improves survival or prevents the need for dialysis. Researchers reported no statistically significant differences in nine other secondary outcomes, including mortality, kidney replacement therapy, and hospital length of stay. The study therefore supports further evaluation of a possible kidney benefit, rather than proving a broad improvement in recovery.
Why Researchers Tested Both Drugs
Norepinephrine is used to raise blood pressure in septic shock, but its vasoconstricting effects may reduce blood flow in some regions, including the kidneys. Dobutamine can increase cardiac output and may increase renal blood flow, though its role in preventing AKI has been debated. Earlier observational research had also linked dobutamine with AKI progression or kidney replacement therapy, leaving uncertainty about its effects during surgery.
The research team, led by Nazrul Islam of the University of Southampton, described the trial as the first large multicenter study specifically testing intraoperative dobutamine during surgical source control, according to the report. They wrote that timely source control is a cornerstone of septic shock care and that instability during shock and surgery can compromise tissue perfusion. The trial’s findings were published in JAMA and presented at the European Society of Intensive Care Medicine’s annual congress in Lisbon.
“Timely source control with surgical intervention is a cornerstone of management in septic shock, necessary in 20% to 30% of patients, and associated with improved outcome.”
— The trial authors
Limits of the Kidney Benefit Evidence
The trial was open-label, and use of advanced hemodynamic monitoring was inconsistent. The intervention was limited to the operating room, so the results do not show whether extending dobutamine after surgery would help or create additional risks. The authors called the findings hypothesis-generating, and said responses may vary among clinical subtypes.
Dobutamine was associated with more tachycardia: 41% versus 29.9% with norepinephrine alone. Mean heart rate at the end of surgery and serious cardiac events—including ventricular tachycardia, atrial fibrillation, premature ventricular contractions and cardiac arrest—were comparable between groups. The study report does not establish whether the findings apply to patients treated outside the participating Chinese hospitals or to different surgical and monitoring practices. It also found no statistically significant differences in mortality, kidney replacement therapy, or hospital stay.
Further Trials and Patient Subgroups
The next step is additional research to test whether the lower AKI incidence can be reproduced and to identify which patients, if any, are most likely to benefit. The authors specifically pointed to studying differences in response across clinical subtypes. Further work could also clarify how hemodynamic monitoring and treatment duration affect outcomes, given that the trial used dobutamine only during surgery and noted inconsistent use of advanced monitoring.
The supplied report does not specify a follow-up trial or a change to clinical guidance. Until further evidence is available, the study’s results should be understood as a finding from one randomized trial, not a universal treatment recommendation.
Key Questions
What did the trial find?
New or worsening AKI within seven days after surgery occurred in 22.8% of patients given dobutamine plus norepinephrine and 34.7% given norepinephrine alone. The adjusted risk ratio was 0.64.
Who took part in the study?
The open-label trial randomized 584 adults with septic shock undergoing surgical source control at 39 tertiary hospitals in China. Patients were enrolled from June 2024 through August 2025.
Did the combination increase heart-related risks?
Tachycardia was more frequent with dobutamine, at 41% compared with 29.9%. The study reported comparable rates of mean heart rate at the end of surgery and serious cardiac adverse events between groups.
Did the treatment reduce deaths or the need for dialysis?
The report found no statistically significant difference between groups in mortality or kidney replacement therapy. The main reported benefit was the lower rate of AKI within seven days.
Does the study establish a new standard of care?
No. The authors described the findings as hypothesis-generating and called for research into which clinical subgroups may respond. The supplied report does not say that clinical guidance has changed.
Source: rss
